Amvisc

Drug Overview

In the highly specialized field of OPHTHALMOLOGY, the success of microsurgical interventions depends heavily on the ability to maintain the structural integrity of the eye’s internal compartments. Amvisc is a premier medical device classified under the VISCOELASTIC AGENT drug class. It is a sterile, non-pyrogenic, high-molecular-weight solution that serves as an indispensable tool for surgeons. Unlike a BIOLOGIC or a VEGF INHIBITOR used for chronic disease management, Amvisc is a specialized surgical aid designed to protect delicate ocular tissues during invasive procedures.

For patients facing vision-threatening conditions like cataracts or retinal detachment, Amvisc provides a “liquid cushion” that ensures the surgeon can operate with maximum precision and safety. Its presence within the eye during surgery is temporary but critical for preventing trauma to the corneal endothelium and other vital structures.

• Generic Name: Sodium Hyaluronate
• US Brand Names: Amvisc, Amvisc Plus
• Drug Class: VISCOELASTIC AGENT (Ophthalmic Viscosurgical Device – OVD)
• Route of Administration: Intraocular Injection (instilled directly into the anterior or posterior segment during surgery)
• FDA Approval Status: Fully FDA-approved as a surgical aid in anterior and posterior segment procedures.

What Is It and How Does It Work? (Mechanism of Action)

Amvisc is composed of a high-purity fraction of sodium hyaluronate, a naturally occurring polysaccharide found in the human vitreous humor and synovial fluid. To understand its role in OPHTHALMOLOGY, one must examine its unique rheological properties—specifically its “visco-cohesive” nature.

At the molecular and physiological level, Amvisc works through a physical mechanism rather than a biochemical pathway. During surgery, the eye is opened, and the natural internal pressure and fluids (aqueous humor) are lost. This can cause the eye to collapse, bringing delicate tissues into contact with surgical instruments or synthetic implants. Amvisc acts as a space-occupying TARGETED THERAPY by providing:

1. Space Maintenance: The high molecular weight and viscosity create a stable volume within the anterior chamber. This keeps the cornea lifted away from the iris and lens, providing the surgeon with a clear “surgical field” and room to manipulate instruments.
2. Endothelial Protection: The corneal endothelium consists of a single layer of cells that do not regenerate. Contact with instruments or ultrasound energy during cataract surgery can kill these cells, leading to permanent corneal clouding. Amvisc coats these cells with a protective molecular shield, absorbing mechanical energy and preventing physical friction.
3. Tissue Manipulation: Its cohesive properties allow it to gently push back the iris or a detached retina, helping the surgeon reposition tissues without causing tears or bleeding.

Because it is “cohesive,” Amvisc sticks together in a mass, making it easier for the surgeon to remove entirely at the end of the procedure, which is vital for maintaining healthy intraocular pressure post-operatively.

FDA-Approved Clinical Indications

Primary Indication: Surgical Aid in Cataract and Retinal Surgery

The primary, FDA-approved use for Amvisc is as an Ophthalmic Viscosurgical Device (OVD) during cataract extraction and intraocular lens (IOL) implantation. It is also utilized in posterior segment surgeries, such as vitrectomies, to aid in the reattachment of the retina and the management of proliferative vitreoretinopathy.

Other Approved & Off-Label Uses

Beyond its primary role, Amvisc is utilized across various surgical sub-specialties in OPHTHALMOLOGY:

• Corneal Transplant Surgery: Used to maintain the anterior chamber and protect the donor graft during keratoplasty.
• Glaucoma Filtering Surgery: Utilized during trabeculectomies to prevent the collapse of the eye and manage the formation of the drainage bleb.
• Ocular Trauma Repair: Helps reform the eye after penetrating injuries, allowing for the stabilization of the blood-retinal barrier during emergency reconstruction.
• IOL Exchange: Provides a protective barrier when removing an old or displaced artificial lens and replacing it with a new one.

Primary Ophthalmology Indications Summary:

• Preserving Visual Acuity: By preventing corneal endothelial cell loss.
• Managing Intraocular Pressure: By ensuring the drainage structures are not mechanically damaged during surgery.
• Stabilizing the Blood-Retinal Barrier: By minimizing surgical inflammation in the posterior segment.

Dosage and Administration Protocols

Unlike topical drops, the dosage of Amvisc is determined by the volume required to fill the surgical space. It is administered via a sterile cannula directly into the eye under microscopic visualization.

Indication	Standard Dose	Frequency
Cataract Surgery	0.2 mL to 0.5 mL (as needed)	Single intraoperative application.
Retinal Reattachment	0.5 mL to 1.0 mL (variable)	Single intraoperative application.
IOL Implantation	Small volume to coat the lens	Single intraoperative application.

Specific Instructions: * Removal: It is a mandatory clinical protocol that the VISCOELASTIC AGENT be thoroughly removed from the eye via irrigation and aspiration at the conclusion of the surgery.

• Storage: Amvisc should be refrigerated but allowed to reach room temperature for 20 to 30 minutes before use to ensure optimal viscosity.

Warning: Dosage must be individualized by a qualified healthcare professional during a surgical procedure.

Clinical Efficacy and Research Results

Clinical study data from 2020 to 2026 confirm that Amvisc remains a gold standard in viscosurgical protection. Efficacy in this category is not measured by a mean gain in letters on a chart, but by the preservation of ocular structures.

Precise Numerical Data:

• Endothelial Cell Loss: In comparative clinical trials, the use of Amvisc during phacoemulsification (cataract surgery) limited endothelial cell loss to less than 5% to 8%, compared to over 20% in procedures where no OVD was used.
• Space Maintenance: Research confirms that high-molecular-weight hyaluronate (like Amvisc) maintains 95% of the anterior chamber depth during IOL insertion, even in eyes with complex anatomy.
• IOP Management: While OVDs can cause temporary pressure spikes, studies show that with proper removal protocols, Intraocular Pressure (IOP) typically returns to within 2 mmHg of baseline within 24 hours.

By protecting the cornea, Amvisc ensures that the patient achieves their maximum potential Best Corrected Visual Acuity (BCVA) after the primary underlying condition is surgically corrected.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Amvisc.

Common Side Effects (>10%)

Because Amvisc is used intraoperatively, side effects are usually related to its presence in the early post-operative period:

• Transient Post-operative IOP Spike: This is the most common issue. If any Amvisc remains in the eye, it can temporarily “clog” the drainage angle, leading to a spike in eye pressure.
• Mild Post-operative Inflammation: A normal response to surgical intervention.

Serious Adverse Events

• Secondary Glaucoma: If the IOP spike is severe and not managed with drops, it can damage the optic nerve.
• Cataract Progression: (Not applicable as it is used to treat cataracts, but mechanical trauma during use can damage the lens capsule).
• Endophthalmitis: A rare but severe intraocular infection associated with any invasive surgery.
• Corneal Edema: Usually temporary, but can occur if the viscoelastic is not used properly to protect the endothelium.

Management Strategies: Surgeons use high-flow irrigation to “wash out” the agent. Post-operative monitoring for “floaters” or sudden pain is essential. If a pressure spike is detected, topical pressure-lowering drops are used as a temporary measure.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is investigating the interaction between sodium hyaluronate and the health of the retinal pigment epithelium (RPE) during complex vitrectomies. There is interest in whether the coating properties of Amvisc can provide neuroprotection to the optic nerve head during the high-pressure phases of fluid-gas exchange in retinal surgery.

Generalization

The development of PRESERVATIVE-FREE and more “dispersive” versions of viscoelastic agents is a major research area. While Amvisc is cohesive, advancements in 2026 are focused on “Visco-adaptive” devices that change properties based on the flow rate of surgical instruments. Research is also ongoing into sustained-release intraocular implants that can be delivered alongside the viscoelastic to manage inflammation for weeks after the surgery.

Severe Disease & Surgical Integration

Research is evaluating Amvisc’s efficacy as an adjunct in end-stage glaucoma surgeries. Maintaining the anterior chamber during the placement of a glaucoma drainage device, it helps prevent blindness caused by flat chambers and corneal-lenticular contact.

Disclaimer: These studies regarding RPE interaction and visco-adaptive delivery are currently in the preclinical or early clinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Establish Baseline Visual Acuity and Tonometry (IOP measurement).
• Ocular Imaging: Optical Coherence Tomography (OCT) is used to check for macular health before surgery.
• Specialized Testing: Specular Microscopy is the most important test; it counts the endothelial cells. If the count is low, a higher volume of Amvisc may be required for protection.
• Screening: Review history for previous ocular surgeries or allergies to sodium hyaluronate.

Monitoring and Precautions

• Vigilance: Monitoring for “rebound” inflammation or sudden spikes in IOP in the first 24 to 48 hours after surgery.
• Lifestyle: Advise the use of UV protection (sunglasses) and strict eyelid hygiene (lid scrubs) post-operatively to prevent infection.
• AREDS2 Formula: May be recommended post-operatively if the patient has underlying macular degeneration to support long-term retinal health.

Do’s and Don’ts:

• DO follow all post-operative drop schedules to manage pressure.
• DO wear your eye shield as directed by the surgeon.
• DON’T rub the eye after surgery, as this can displace the incision.
• DON’T perform heavy lifting or bending, which can increase eye pressure.

Legal Disclaimer

This guide is for informational purposes only and does not replace the advice of your surgeon. Amvisc is a medical device used only in a surgical setting. Any concerns regarding surgical risks or the use of intraoperative aids should be discussed directly with your ophthalmologist. Information is accurate as of early 2026.